WHITE PAPER
Overview of the NASH Development Landscape: Opportunities and Lessons Learned
Sep 19, 2023

NASH occupies a unique position — despite very active clinical development driven by an estimated global incidence of 33% in the overweight population, there are not yet any FDA approved therapies. As such, there remains significant untapped commercial potential in the NASH market which is estimated at upwards of $25 billion by 2028. However, in spite of heavy pharmaceutical interest and investment, NASH development has been riddled with a multitude of failed candidates.

Contact Us